Phenotype
|
Fish
|
Conditions
|
Figures
|
whole organism decreased life span, exacerbated
|
AB + MO1-irf8
|
bacterial treatment by injection: Streptococcus iniae
|
Fig. 5
from Vincent et al., 2017
|
whole organism decreased life span, exacerbated
|
AB/TL + MO1-irf8
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 4
from Masud et al., 2019
|
whole organism has extra parts of type neutrophil, abnormal
|
TU + MO1-irf8
|
bacterial treatment by injection: Acinetobacter baumannii ATCC 17978
|
Fig. S2
from Bhuiyan et al., 2016
|
whole organism has fewer parts of type macrophage, abnormal
|
TU + MO1-irf8
|
bacterial treatment by injection: Acinetobacter baumannii ATCC 17978
|
Fig. S2
from Bhuiyan et al., 2016
|
head epidermis irg1l expression position, ameliorated
|
WT + MO1-irf8
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 2
from Hall et al., 2014
|
caudal fin regenerating fin il1b expression increased amount, abnormal
|
WT + MO1-irf8
|
amputation: caudal fin
|
Fig. 5
from Hasegawa et al., 2017
|
epithelial cell irg1l expression position, ameliorated
|
WT + MO1-irf8
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 2
from Hall et al., 2014
|
trunk acod1 expression amount, ameliorated
|
WT + MO1-irf8
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 1
from Hall et al., 2013
|
defense response to fungus process quality, abnormal
|
WT + MO1-irf8
|
standard conditions
|
Fig. 5
from Knox et al., 2014
|
microglial cell decreased amount, abnormal
|
WT + MO1-irf8
|
standard conditions
|
Fig. 2
from Li et al., 2011
|
macrophage absent, abnormal
|
WT + MO1-irf8
|
standard conditions
|
Fig. 2
from Li et al., 2011
|
vasculature acod1 expression amount, ameliorated
|
WT + MO1-irf8
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 1
from Hall et al., 2013
|
regenerating fin apoptotic process occurrence, ameliorated
|
WT + MO1-irf8
|
chemical treatment by environment: dexamethasone, amputation: caudal fin
|
Fig. 5
from Hasegawa et al., 2017
|
neuromast epithelium irg1l expression position, ameliorated
|
WT + MO1-irf8
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 2
from Hall et al., 2014
|
macrophage decreased amount, abnormal
|
WT + MO1-irf8
|
standard conditions
|
Fig. 2
from Li et al., 2011
|
olfactory epithelium irg1l expression position, ameliorated
|
WT + MO1-irf8
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 2
from Hall et al., 2014
|
blood cebpb expression amount, ameliorated
|
WT + MO1-irf8
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 2
from Hall et al., 2013
|
neutrophil increased amount, abnormal
|
WT + MO1-irf8
|
standard conditions
|
Fig. 3,
Fig. 4
from Li et al., 2011
|
whole organism lacks all parts of type macrophage, abnormal
|
WT + MO1-irf8
|
standard conditions
|
Fig. 6
from Shiau et al., 2013
|
fin regeneration increased duration, abnormal
|
WT + MO1-irf8
|
physical alteration: anatomical structure
|
Fig. 5
from Li et al., 2012
|
macrophage decreased amount, abnormal
|
WT + MO1-irf8
|
amputation: caudal fin
|
Fig. 4
from Hasegawa et al., 2017
|
whole organism decreased life span, abnormal
|
WT + MO1-irf8
|
standard conditions
|
Fig. 5
from Knox et al., 2014
|
hindbrain acod1 expression amount, ameliorated
|
WT + MO1-irf8
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 1
from Hall et al., 2013
|
regenerating fin apoptotic process increased occurrence, abnormal
|
WT + MO1-irf8
|
amputation: caudal fin
|
Fig. 4 ,
Fig. 5
from Hasegawa et al., 2017
|
midbrain acod1 expression amount, ameliorated
|
WT + MO1-irf8
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 1
from Hall et al., 2013
|
macrophage acod1 expression amount, ameliorated
|
WT + MO1-irf8
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 1
from Hall et al., 2013
|
macrophage decreased amount, abnormal
|
gl22Tg + MO1-irf8
|
standard conditions
|
Fig. S1
from Yan et al., 2015
|
neutrophil increased amount, abnormal
|
i113Tg + MO1-irf8
|
standard conditions
|
Fig. 4
from Li et al., 2011
|
macrophage decreased amount, abnormal
|
i113Tg + MO1-irf8
|
standard conditions
|
Fig. 2
from Li et al., 2011
|
macrophage decreased amount, abnormal
|
nz50Tg + MO1-irf8
|
chemical treatment: prostaglandin E2
|
Fig. S4
from Feng et al., 2012
|
neutrophil increased amount, abnormal
|
nz50Tg + MO1-irf8
|
chemical treatment: prostaglandin E2
|
Fig. S4
from Feng et al., 2012
|
neutrophil increased amount, abnormal
|
nz50Tg + MO1-irf8
|
standard conditions
|
Fig. S1
from Yan et al., 2015
Fig. S4
from Feng et al., 2012
|
macrophage decreased amount, abnormal
|
nz50Tg + MO1-irf8
|
standard conditions
|
Fig. S4
from Feng et al., 2012
|
trunk vasculature morphology, ameliorated
|
s843Tg + MO1-irf8
|
bacterial treatment by injection: Mycobacterium marinum M
|
Fig. 3
from Torraca et al., 2017
|
trunk vasculature response to bacterium process quality, abnormal
|
s843Tg + MO1-irf8
|
bacterial treatment by injection: Mycobacterium marinum M
|
Fig. 3
from Torraca et al., 2017
|
myelin accumulating cell cell projection amount, ameliorated
|
ue2Tg + MO1-irf8 (AB)
|
bacterial treatment by injection: Mycobacterium leprae, chemical treatment by injection: clondronate(2-), chemical ablation: macrophage
|
Fig. 5
from Madigan et al., 2017
|
neuron myelin sheath disorganized, ameliorated
|
ue2Tg + MO1-irf8 (AB)
|
bacterial treatment by injection: Mycobacterium leprae, chemical treatment by injection: clondronate(2-), chemical ablation: macrophage
|
Fig. 5
from Madigan et al., 2017
|
macrophage decreased amount, abnormal
|
uwm12Tg + MO1-irf8
|
standard conditions
|
Fig. S2
from Knox et al., 2014
|
defense response to fungus process quality, abnormal
|
uwm12Tg + MO1-irf8
|
fungal treatment: Aspergillus fumigatus
|
Fig. 2
from Knox et al., 2014
|
macrophage aplastic, abnormal
|
uwm12Tg + MO1-irf8
|
standard conditions
|
Fig. S2
from Knox et al., 2014
|
whole organism decreased life span, abnormal
|
uwm12Tg + MO1-irf8
|
fungal treatment: Aspergillus fumigatus
|
Fig. 2
from Knox et al., 2014
|
whole organism decreased life span, exacerbated
|
uwm12Tg + MO1-irf8
|
bacterial treatment by injection: Streptococcus iniae
|
Fig. 1
from Vincent et al., 2017
|
macrophage decreased amount, abnormal
|
w200Tg + MO1-irf8
|
control
|
Fig. 5
from Pagán et al., 2015
|
macrophage absent, abnormal
|
uwm12Tg; uwm24Tg + MO1-irf8
|
physical alteration: caudal fin
|
Fig. 2
from Tauzin et al., 2014
|
neutrophil response to wounding process quality, abnormal
|
uwm12Tg; uwm24Tg + MO1-irf8
|
physical alteration: caudal fin
|
Fig. 2
from Tauzin et al., 2014
|
neutrophil chemotaxis process quality, abnormal
|
uwm12Tg; uwm24Tg + MO1-irf8
|
physical alteration: caudal fin
|
Fig. 2
from Tauzin et al., 2014
|
whole organism lacks all parts of type macrophage, abnormal
|
nlrc3lst73/+ + MO1-irf8
|
standard conditions
|
Fig. 6
from Shiau et al., 2013
|
whole organism lacks all parts of type macrophage, abnormal
|
nlrc3lst73/st73 + MO1-irf8
|
standard conditions
|
Fig. 6
from Shiau et al., 2013
|
regenerating fin apoptotic process occurrence, ameliorated
|
WT + MO1-il1b + MO1-irf8
|
amputation: caudal fin
|
Fig. 5
from Hasegawa et al., 2017
|
neutrophil decreased amount, ameliorated
|
nz50Tg + MO1-irf8 + MO3-septin15
|
bacterial treatment by injection: Shigella flexneri
|
Fig. 3
from Mazon-Moya et al., 2017
|
whole organism decreased life span, abnormal
|
nz50Tg + MO1-irf8 + MO3-septin15
|
bacterial treatment by injection: Shigella flexneri
|
Fig. 3
from Mazon-Moya et al., 2017
|
whole organism decreased life span, exacerbated
|
uwm36Tg + MO1-irf8
|
bacterial treatment by injection: Streptococcus iniae
|
Fig. 5
from Vincent et al., 2017
|
muscle cell cell wall repair process quality, abnormal
|
gl22Tg + MO1-irf8 + MO1-spi1b + MO3-csf3r
|
light damage: sarcolemma: muscle cell
|
Fig. 1
from Middel et al., 2016
|
macrophage absent, abnormal
|
gl22Tg + MO1-irf8 + MO1-spi1b + MO3-csf3r
|
light damage: sarcolemma: muscle cell
|
Fig. 1
from Middel et al., 2016
|
trunk vasculature morphology, ameliorated
|
cxcr4bt26035/t26035; s843Tg + MO1-irf8
|
bacterial treatment by injection: Mycobacterium marinum M
|
Fig. 3
from Torraca et al., 2017
|
trunk vasculature response to bacterium process quality, abnormal
|
cxcr4bt26035/t26035; s843Tg + MO1-irf8
|
bacterial treatment by injection: Mycobacterium marinum M
|
Fig. 3
from Torraca et al., 2017
|
liver increased size, abnormal
|
gz32Tg; nz50Tg + MO1-irf8
|
chemical treatment: doxycycline monohydrate
|
Fig. 3
from Yan et al., 2015
|
liver neutrophil increased amount, abnormal
|
gz32Tg; nz50Tg + MO1-irf8
|
chemical treatment: doxycycline monohydrate
|
Fig. 3
from Yan et al., 2015
|
macrophage decreased amount, abnormal
|
hzm1Et; io006Tg + MO1-irf8
|
chemical treatment: prostaglandin E2
|
Fig. 3
from Feng et al., 2012
|
macrophage decreased amount, abnormal
|
hzm1Et; io006Tg + MO1-irf8
|
standard conditions
|
Fig. 3
from Feng et al., 2012
|
mucus secreting cell decreased amount, abnormal
|
hzm1Et; io006Tg + MO1-irf8
|
standard conditions
|
Fig. 3
from Feng et al., 2012
|
neutrophil increased amount, abnormal
|
hzm1Et; io006Tg + MO1-irf8
|
standard conditions
|
Fig. 3
from Feng et al., 2012
|
mucus secreting cell proliferative, abnormal
|
hzm1Et; io006Tg + MO1-irf8
|
standard conditions
|
Fig. 3
from Feng et al., 2012
|
mucus secreting cell proliferative, abnormal
|
hzm1Et; io006Tg + MO1-irf8
|
chemical treatment: prostaglandin E2
|
Fig. 3
from Feng et al., 2012
|
neutrophil increased amount, abnormal
|
hzm1Et; io006Tg + MO1-irf8
|
chemical treatment: prostaglandin E2
|
Fig. 3
from Feng et al., 2012
|
macrophage absent, abnormal
|
hzm1Et; io006Tg; nz50Tg + MO1-irf8
|
control
|
Fig. 3
from Antonio et al., 2015
|
macrophage absent, abnormal
|
hzm1Et; io006Tg; nz50Tg + MO1-irf8
|
resection: caudal fin
|
Fig. 3
from Antonio et al., 2015
|